These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. Gurska LM; Okabe R; Schurer A; Tong MM; Soto M; Choi D; Ames K; Glushakow-Smith S; Montoya A; Tein E; Miles LA; Cheng H; Hankey-Giblin P; Levine RL; Goel S; Halmos B; Gritsman K Clin Cancer Res; 2023 Mar; 29(5):943-956. PubMed ID: 36537918 [TBL] [Abstract][Full Text] [Related]
3. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172 [TBL] [Abstract][Full Text] [Related]
4. Impact of heat stress on prolactin-mediated ovarian JAK-STAT signaling in postpubertal gilts. Roach CM; Bidne KL; Romoser MR; Ross JW; Baumgard LH; Keating AF J Anim Sci; 2022 Jul; 100(7):. PubMed ID: 35772766 [TBL] [Abstract][Full Text] [Related]
5. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders. Roskoski R Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738 [TBL] [Abstract][Full Text] [Related]
6. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms. Hao X; Xing W; Yuan J; Wang Y; Bai J; Bai J; Zhou Y Invest New Drugs; 2020 Jun; 38(3):610-620. PubMed ID: 31227936 [TBL] [Abstract][Full Text] [Related]